OVERVIEW

The New Obesity Management Landscape: Beyond the scale - Optimizing quality, safety and individualization of Weight Loss in the Incretin Era is organized by David Geffen School of Medicine (DGSOM) at UCLA, Office of Continuing Medical Education and will be held on May 01, 2027 at Ronald Reagan UCLA Medical Center, Los Angeles, California, United States of America.

Overview:
GLP-1 and dual-incretin therapies now produce weight loss that is close to what was possible only with surgery. Clinicians face new questions; we have moved on from do they work to how do we support our patients long term with them? How much of the weight lost is lean mass? Which patients develop nutrient deficiencies, disordered eating, or hair and facial changes on treatment? When are non-incretin agents or combination regimens appropriate? What happens when therapy is interrupted for surgery, pregnancy, or supply problems? And how do we reach patients with rare genetic obesity, or those who face economic and structural barriers?

This one-day, accredited program addresses those questions through keynote, lecture, fireside-chat, and integrated Q&A formats. Faculty will present current evidence on pathophysiology, pharmacotherapy, nutrition, exercise, sleep, procedural options, and payer navigation.

Objectives:
At the conclusion of this activity, learners will be able to:

  1. Evaluate the evidence on lean mass loss during incretin therapy and apply strategies to monitor and preserve muscle and physical function.
  2. Compare GLP-1, dual-, and multi-agonist therapies with non-incretin agents, and select, sequence, or combine medications based on patient characteristics.
  3. Design nutrition and exercise plans that support high-quality weight loss and reduce the risk of nutrient deficiencies.
  4. Recognize and manage obstructive sleep apnea and circadian factors in patients receiving weight-management therapy.
  5. Identify patients who warrant evaluation for monogenic or syndromic obesity or who carry eating-disorder risk, and apply safety frameworks when prescribing.
  6. Plan for incretin interruptions around surgery, pregnancy, and supply disruptions, and manage hair loss and facial volume loss during rapid weight loss.
  7. Determine when to refer for endobariatric procedures or bariatric surgery, and how to combine surgery with post-operative pharmacotherapy.
  8. Apply strategies to address cost, food access, weight bias, and payer requirements (formularies, prior authorization) so more patients can start and stay on treatment.

KEY DATES

Registrations Open
10 Nov, 2026
Registrations Open
Event Start Date
01 May, 2027
Event Start Date
Event End Date
01 May, 2027
Event End Date
Credits

Accreditation:
The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved by the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

  • 7 AMA PRA Category 1 Credits™
  • TARGET AUDIENCE

    PhysicianNursesMedical StudentsAllied Health ProfessionalsFellows

    SPECIALITIES

    Endocrinology, Metabolism and Diabetes

    SUGGESTED HOTELS

    CONFERENCE VENUE

    LocationRonald Reagan UCLA Medical Center
    Tamkin Auditorium, (B-130 RRMC), 757 Westwood Plaza

    RELATED CONFERENCES & LIVE WEBINARS